Gingival mesenchymal stem cell-derived exosomal miR-23a-3p targets IL-6R to attenuate autoimmune insulitis: a cell-free therapeutic strategy for type 1 diabetes
GMSC-EXO deliver miR-23a-3p to target IL-6R, restoring immune balance and mitigating insulitis in T1D. This study highlights the miR-23a-3p/IL-6R axis as a therapeutic target and establishes GMSC-EXO as a safe, cell-free strategy for autoimmune disorders. These findings provide a foundation for engineering exosome-based therapies in diabetes and related conditions.
Authors
- Qiang Ao (ORCID: https://orcid.org/0000-0002-1309-1971)
- Xiaohong Tian (ORCID: https://orcid.org/0000-0003-3580-7501)
- Qing Qu (ORCID: https://orcid.org/0000-0001-7475-7063)
- Siyu Liu (ORCID: https://orcid.org/0000-0001-7089-2006)
- Ziyu Liu (ORCID: https://orcid.org/0000-0001-7149-4827)
- Yong Long (ORCID: https://orcid.org/0009-0006-1571-8981)
- Bin Fu (ORCID: https://orcid.org/0000-0001-6686-7561)
- Weijian Hou
- Wumei Wei
- Xiaoli Liu (ORCID: https://orcid.org/0009-0006-0634-2652)
Institutions
- West China Medical Center of Sichuan University (CN)
- Shenyang Center for Disease Control and Prevention (CN)
- China Medical University (CN)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s13287-025-04744-1
- Citations
- 3
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Natural Science Foundation of Liaoning Province
- China Medical University
- National Key Research and Development Program of China